

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

VOLUNTARY ANNOUNCEMENT

MILESTONE PAYMENT RECEIVED FROM ROCHE FOR THE FIRST PARTICIPANT DOSED IN PHASE I CLINICAL TRIAL OF QX031N

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company received a milestone payment from its partner, F. Hoffmann-La Roche Ltd (“**Roche**”) on May 27, 2026, triggered by the dosing of the first participant in the Phase I clinical trial of the QX031N (Roche research and development code: RG6981) project.

The QX031N has initiated a Phase I, first-in-human, randomized, investigator- and participant-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in New Zealand, aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of QX031N in healthy participants, participants with chronic obstructive pulmonary disease (“**COPD**”) and participants with asthma. The first participant of this study was dosed on March 27, 2026.

On October 28, 2025, the Company entered into a global exclusive collaboration and license agreement with Roche, pursuant to which the Company grants Roche the global exclusive right to develop, manufacture, and commercialize QX031N.

ABOUT QX031N/RG6981

QX031N is a clinical-stage long-acting bispecific antibody that targets both human thymic stromal lymphopoietin (TSLP) and human interleukin-33 (IL-33).

TSLP and IL-33 are proteins called alarmins that are released in the body in response to external factors such as allergens, viruses, pollution, and mechanical stimuli. They have been shown to be involved in respiratory diseases like COPD and asthma, and play important roles in the inflammatory processes. QX031N is expected to be developed for the treatment of respiratory diseases such as COPD and asthma, and holds the potential to become a “First-in-class” and “Best-in-disease” therapy.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, May 27, 2026

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.